InnoCare Pharma Limited

HKSE 9969.HK

InnoCare Pharma Limited Return on Capital Employed (ROCE) for the year ending December 31, 2023: -7.78%

InnoCare Pharma Limited Return on Capital Employed (ROCE) is -7.78% for the year ending December 31, 2023, a 26.78% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

InnoCare Pharma Limited Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -10.63%, a -4,199.39% change year over year.
InnoCare Pharma Limited Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -0.25%, a 97.64% change year over year.
InnoCare Pharma Limited Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -10.49%, a 87.56% change year over year.
InnoCare Pharma Limited Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -84.29%, a -224.74% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

HKSE: 9969.HK

InnoCare Pharma Limited

CEO	Dr. Jisong Cui Ph.D.
IPO Date	March 23, 2020
Location	China
Headquarters	Building 8
Employees	1,089
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Key trends

Past 5 years